Rama Khokha, PhD, summarized findings from studies of epigenetic inhibitors, PARP inhibitors and metabolic inhibitors in her plenary lecture on Wednesday.

On Thursday, Prudence Francis, MD, addressed what oncologists and researchers have learned and how that knowledge can translate into treatment in the future.

Thursday’s General Session included data from trials looking at the efficacy of the next-generation SERD camizestrant, the investigational AKT inhibitor capivasertib, and the use of circulating tumor cell count to guide the choice between chemotherapy and endocrine therapy.

During a Thursday debate session, Ruth O’Regan, MD, and Debra Patt, MD, PhD, MBA, argued whether the impacts of CDK4/6 inhibitors had more to do with patient selection or molecular structure and potency of agents.

Geoffrey M. Wahl, PhD, received the Brinker Award for Scientific Distinction in Basic Science on Thursday and emphasized the necessity of interdisciplinary alliances and mentorship to further scientific research.

Wendy A. Woodward, MD, PhD, leads a session on Friday looking at technological advances in radiation oncology and the impact on both patients and clinicians.

Diana M. Cittelly, PhD, will moderate a session on Friday looking at how the tumor microenvironment has emerged as a critical driver of tumor progression.